Cargando…

Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study

INTRODUCTION: The 16-week randomised, placebo-controlled INCREASE trial (RCT) met its primary end-point by improving 6-min walk distance (6MWD) in patients receiving inhaled treprostinil for pulmonary hypertension due to interstitial lung disease (PH-ILD). The open-label extension (OLE) evaluated lo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Waxman, Aaron, Restrepo-Jaramillo, Ricardo, Thenappan, Thenappan, Engel, Peter, Bajwa, Abubakr, Ravichandran, Ashwin, Feldman, Jeremy, Hajari Case, Amy, Argula, Rahul G., Tapson, Victor, Smith, Peter, Deng, Chunqin, Shen, Eric, Nathan, Steven D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2023
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307984/ https://www.ncbi.nlm.nih.gov/pubmed/37080567 http://dx.doi.org/10.1183/13993003.02414-2022

Ejemplares similares

Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial
por: Nathan, Steven D., et al.
Publicado: (2021)

The safety and tolerability of inhaled treprostinil in patients with pulmonary hypertension and chronic obstructive pulmonary disease
por: Bajwa, Abubakr A., et al.
Publicado: (2017)

BREEZE: Open‐label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension
por: Spikes, Leslie A., et al.
Publicado: (2022)

Characterisation of cough evoked by inhaled treprostinil and treprostinil palmitil
por: Chapman, Richard W., et al.
Publicado: (2021)

A multicenter retrospective study of patients with pulmonary hypertension transitioned from inhaled to oral treprostinil
por: Zwicke, Diane L., et al.
Publicado: (2021)

Rapid Transition from Inhaled Iloprost to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension
por: Bourge, Robert C, et al.
Publicado: (2013)

Inhaled Treprostinil in Pulmonary Hypertension in the Context of Interstitial Lung Disease: A Success, Finally
por: Behr, Jürgen
Publicado: (2021)

Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension
por: Raina, Amresh, et al.
Publicado: (2013)

Inhaled treprostinil: a therapeutic review
por: Channick, Richard N, et al.
Publicado: (2012)

Inhaled treprostinil and pulmonary arterial hypertension
por: Nadler, Samuel T, et al.
Publicado: (2010)

Effect of Inhalation Profile on Delivery of Treprostinil Palmitil Inhalation Powder
por: Gauani, Helena, et al.
Publicado: (2023)

The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD
por: Kolb, Martin, et al.
Publicado: (2022)

Implementing the EXPEDITE parenteral induction protocol: Rapid parenteral treprostinil titration and transition to oral treprostinil
por: Kingrey, John F., et al.
Publicado: (2023)

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
por: Hill, Nicholas S., et al.
Publicado: (2022)

Pulmonary hypertension in chronic kidney disease: a hemodynamic characterization
por: Thenappan, Thenappan
Publicado: (2017)

Clinical Overview of Progressive Fibrotic Interstitial Lung Disease
por: Case, Amy Hajari
Publicado: (2022)

Survival and drug persistence in patients receiving inhaled treprostinil at doses greater than 54 µg (nine breaths) four times daily
por: Shapiro, Shelley, et al.
Publicado: (2021)

Pulmonary Arterial Hypertension and Sex in the Right Ventricle: It Is an Interesting Picture!
por: Thenappan, Thenappan, et al.
Publicado: (2020)

Late-onset pulmonary arterial hypertension in repaired D-transposition of great arteries: an uncommon complication
por: Baskaran, Janani, et al.
Publicado: (2017)

Inhaled Treprostinil after Initial Clinical Worsening: To Continue or Not to Continue, That’s the Question
por: Jin, Qi, et al.
Publicado: (2022)

Efficacy, safety, and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary arterial hypertension
por: Kuwana, Masataka, et al.
Publicado: (2023)

Recommendations for the use of oral treprostinil in clinical practice: a Delphi consensus project pulmonary circulation
por: Rahaghi, Franck F., et al.
Publicado: (2017)

Resistance over compliance describes right ventricular afterload better than resistance-compliance time: a friendly amendment
por: Thenappan, Thenappan, et al.
Publicado: (2017)

Treatment Targets for Right Ventricular Dysfunction in Pulmonary Arterial Hypertension
por: Prisco, Sasha Z., et al.
Publicado: (2020)

Pulmonary tumor thrombotic microangiopathy: Exploration into current diagnostic aids and therapeutics
por: Ramakrishnan, Pavithra, et al.
Publicado: (2023)

Combination therapy with riociquat and inhaled treprostinil in inoperable and progressive chronic thromboembolic pulmonary hypertension
por: Swisher, John W., et al.
Publicado: (2016)

Development and Characterization of Treprostinil Palmitil Inhalation Aerosol for the Investigational Treatment of Pulmonary Arterial Hypertension
por: Plaunt, Adam J., et al.
Publicado: (2021)

Ingenuity pathway analysis of the human cardiac cell Atlas identifies differences between right and left ventricular cardiomyocytes
por: Prisco, Sasha Z., et al.
Publicado: (2022)

Sex differences in right ventricular function between Groups 1 and 3 pulmonary hypertension
por: Kazmirczak, Felipe, et al.
Publicado: (2023)

Treprostinil for pulmonary hypertension
por: Skoro-Sajer, Nika, et al.
Publicado: (2008)

Implantable system for treprostinil and lung transplantation: case series from delivery for pulmonary arterial hypertension study
por: Feldman, Jeremy P., et al.
Publicado: (2021)

Inhaled treprostinil vs iloprost: Comparison of adherence, persistence, and health care resource utilization in patients with pulmonary arterial hypertension
por: Burger, Charles D, et al.
Publicado: (2023)

Chronic use of PAH-specific therapy in World Health Organization Group III Pulmonary Hypertension: a systematic review and meta-analysis
por: Prins, Kurt W., et al.
Publicado: (2017)

With No Lysine Kinase 1 Promotes Metabolic Derangements and RV Dysfunction in Pulmonary Arterial Hypertension
por: Prisco, Sasha Z., et al.
Publicado: (2021)

Ketone bodies in right ventricular failure: A unique therapeutic opportunity
por: Blake, Madelyn, et al.
Publicado: (2023)

Transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients
por: Holthaus, Nathan, et al.
Publicado: (2019)

Data on clinical and economic burden associated with pulmonary arterial hypertension related hospitalizations in the United States
por: Chaturvedi, Abhishek, et al.
Publicado: (2020)

Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension
por: Chen, Hubert, et al.
Publicado: (2013)

Robotic-assisted vs. open radical prostatectomy: an update to the never-ending debate
por: Chandrasekar, Thenappan, et al.
Publicado: (2018)

Carvedilol for Treatment of Right Ventricular Dysfunction in Pulmonary Arterial Hypertension
por: Thenappan, Thenappan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_05mrlq8u01b5liv2kvrusv5jpd